Core Laboratories (CLB) Current Deferred Revenue (2022 - 2026)

Core Laboratories has reported Current Deferred Revenue for 5 years, with the latest figure at $4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 51.82% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (down 51.82% YoY), and the FY2025 full-year result was $5.6 million, down 40.51% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $4.7 million, down from $5.6 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $9.8 million in Q1 2025, with the low at $4.6 million in Q3 2023.
• Historically, Current Deferred Revenue has averaged $6.5 million across 5 years, with a median of $5.6 million in 2025.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue jumped 96.26% — and 2026, when it tumbled 51.82%.
• Core Laboratories' Current Deferred Revenue stood at $5.9 million in 2022, then dropped by 19.98% to $4.8 million in 2023, then jumped by 96.26% to $9.3 million in 2024, then plunged by 40.51% to $5.6 million in 2025, then decreased by 15.2% to $4.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $4.7 million (Q1 2026), $5.6 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.